


## Data Sheet

<b>Product Name:</b>	Treprostinil
<b>Cat. No.:</b>	CS-7872
<b>CAS No.:</b>	81846-19-7
<b>Molecular Formula:</b>	C <sub>23</sub> H <sub>34</sub> O <sub>5</sub>
<b>Molecular Weight:</b>	390.51
<b>Target:</b>	Prostaglandin Receptor
<b>Pathway:</b>	GPCR/G Protein
<b>Solubility:</b>	DMSO : $\geq 125$ mg/mL (320.09 mM)



### BIOLOGICAL ACTIVITY:

Treprostinil (LRX-15) is a potent **DP1** and **EP2** agonist with **EC<sub>50</sub>** values of  $0.6 \pm 0.1$  and  $6.2 \pm 1.2$  nM, respectively. **IC<sub>50</sub> & Target:** **EC<sub>50</sub>:**  $0.6 \pm 0.1$  nM (DP1),  $6.2 \pm 1.2$  nM (EP2)<sup>[1]</sup> **In Vitro:** Treprostinil has high affinity for the DP1, EP2 and IP receptors ( $K_i = 4.4$ , 3.6 and 32 nM, respectively), low affinity for EP1 and EP4 receptors and even lower affinity for EP3, FP and TP receptors. Activation of IP, DP1 and EP2 receptors, as with treprostinil, can all result in vasodilatation of human pulmonary arteries<sup>[1]</sup>. Treprostinil inhibits viability of cultured endothelial colony forming cells. Endothelial colony forming cells proliferation is stimulated by conditioned media from Treprostinil pretreated mesenchymal stem cells<sup>[5]</sup>. **In Vivo:** Inhaled treprostinil sodium, a prostacyclin analog, is the most recent agent to receive FDA approval for the treatment of a fatal orphan disease: pulmonary arterial hypertension (PAH)<sup>[2]</sup>. Treprostinil preserves the sinusoidal endothelial cell lining and reduces platelet deposition early post-transplantation compared to placebo. Hepatic tissue blood flow is significantly compromised in the placebo group, whereas treprostinil maintains blood flow similar to normal levels<sup>[3]</sup>. Treprostinil treatment significantly increases the vessel-forming ability of endothelial colony forming cells combined with mesenchymal stem cells in Matrigel implanted in nude mice. Silencing VEGF-A gene in mesenchymal stem cells also blocks the pro-angiogenic effect of Treprostinil<sup>[4]</sup>. Treprostinil is most efficacious in raising intracellular cAMP levels in murine and human hematopoietic stem and progenitor cells<sup>[5]</sup>. Treatment with Treprostinil significantly reduces the recruitment of cells compared to normoxic mice. Treprostinil also reduces right ventricular systolic pressure and slightly reduces the vascular remodelling but fails to reverse the right ventricular hypertrophy<sup>[6]</sup>.

### PROTOCOL (Extracted from published papers and Only for reference)

**Cell Assay:** <sup>[5]</sup> Human or murine hematopoietic stem and progenitor cells are incubated in the presence of vehicle or the combination of 10  $\mu$ M Treprostinil and 30  $\mu$ M forskolin at 37°C for 1 hour and 24 hours. After washing with phosphate-buffered saline at 4°C, cells are stained for externalized phosphatidylserine with the apoptosis kit<sup>[5]</sup>. **Animal Administration:** <sup>[3]</sup><sup>[6]</sup> Rats<sup>[3]</sup>

Male Lewis rats weighing 200-300 g are used in the study. Donor animals receive treprostinil or placebo 24 h before hepatectomy and the corresponding recipient animal receive the similar treatment until the time of sacrifice. The surgeon is blinded to treatment. Recipients are sacrificed at 1, 3, 6, 24 and 48 h post-transplantation to examine the early events after IRI. Treprostinil (100 ng/kg/min) or placebo is administered subcutaneously via an Alzet implantable osmotic pump. This dose is selected to achieve a steady-state plasma concentration in the range of 5-20 ng/mL<sup>[3]</sup>.

Mice<sup>[6]</sup>

Bone marrow transplanted (BMT) mice are divided into five different groups with each group consisting of 6 to 10 mice. One group of mice is exposed to hypoxia (10% inspired oxygen fraction) in a normobaric chamber whereas the second group (control BMT) of animals are placed in a normoxic chamber with a normal oxygen environment (21% inspired O<sub>2</sub> fraction) for 28 days. Sham group

mice receive saline treatment whereas two other groups of mice receive Treprostinil infusions of different dose levels (14 ng/kg and 70 ng/kg per minute) and are exposed to hypoxia for 4 weeks. For comparison, human infusion rates in PAH therapy vary from 10 to 60 ng/kg per min<sup>[6]</sup>.

## References:

- [1]. Whittle BJ, et al. Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: treprostinil is a potent DP1 and EP2 agonist. *Biochem Pharmacol.* 2012 Jul 1;84(1):68-75.
- [2]. Ferrantino M, et al. Inhaled treprostinil sodium for the treatment of pulmonary arterial hypertension. *Expert Opin Pharmacother.* 2011 Nov;12(16):2583-93.
- [3]. Ghonem N, et al. Treprostinil, a prostacyclin analog, ameliorates ischemia-reperfusion injury in rat orthotopic liver transplantation. *Am J Transplant.* 2011 Nov;11(11):2508-16.
- [4]. Smadja DM, et al. Treprostinil indirectly regulates endothelial colony forming cell angiogenic properties by increasing VEGF-A produced by mesenchymal stem cells. *Thromb Haemost.* 2015 Oct;114(4):735-47.
- [5]. Kazemi Z, et al. Repurposing Treprostinil for Enhancing Hematopoietic Progenitor Cell Transplantation. *Mol Pharmacol.* 2016 Jun;89(6):630-44.
- [6]. Nikam VS, et al. Treprostinil inhibits the recruitment of bone marrow-derived circulating fibrocytes in chronic hypoxic pulmonary hypertension. *Eur Respir J.* 2010 Dec;36(6):1302-14.

## CAIndexNames:

Acetic acid, 2-[[[(1R,2R,3aS,9aS)-2,3,3a,4,9,9a-hexahydro-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-1H-benz[f]inden-5-yl]oxy]-

## SMILES:

OC(COC1=CC=CC2=C1C[C@](C[C@@H](O)[C@@H]3CC[C@@H](O)CCCC([H])[C@]3([H])C2)=O

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 732-484-9848 Fax: 888-484-5008 E-mail: [sales@ChemScene.com](mailto:sales@ChemScene.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA